Q3 Earnings Forecast for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for Candel Therapeutics in a research report issued on Monday, June 30th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright has a "Buy" rating and a $23.00 price objective on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share. HC Wainwright also issued estimates for Candel Therapeutics' Q4 2025 earnings at ($0.17) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at $0.06 EPS and FY2029 earnings at $1.09 EPS.

Separately, Wall Street Zen raised Candel Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $22.00.

Candel Therapeutics Price Performance

Shares of CADL traded up $0.11 during trading hours on Tuesday, reaching $5.10. The stock had a trading volume of 618,916 shares, compared to its average volume of 1,474,370. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.64 and a current ratio of 4.64. Candel Therapeutics has a 12 month low of $3.79 and a 12 month high of $14.60. The stock has a market capitalization of $255.51 million, a PE ratio of -3.81 and a beta of -0.91. The company's 50-day moving average is $5.22 and its two-hundred day moving average is $6.73.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.37.

Hedge Funds Weigh In On Candel Therapeutics

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of Candel Therapeutics in the 4th quarter valued at $30,000. Russell Investments Group Ltd. raised its stake in shares of Candel Therapeutics by 75.1% in the fourth quarter. Russell Investments Group Ltd. now owns 3,753 shares of the company's stock worth $33,000 after purchasing an additional 1,610 shares during the last quarter. Taylor Financial Group Inc. bought a new position in Candel Therapeutics during the 1st quarter valued at $56,000. Wells Fargo & Company MN lifted its position in shares of Candel Therapeutics by 63.6% during the fourth quarter. Wells Fargo & Company MN now owns 10,122 shares of the company's stock valued at $88,000 after purchasing an additional 3,935 shares in the last quarter. Finally, Private Advisor Group LLC purchased a new position in shares of Candel Therapeutics in the 1st quarter worth approximately $58,000. Institutional investors own 13.93% of the company's stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.